Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

32.56 +0.59 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,441,537
Open 32.11
Bid (Size) 32.21 (2)
Ask (Size) 33.90 (7)
Prev. Close 31.97
Today's Range 31.71 - 33.89
52wk Range 27.77 - 138.52
Shares Outstanding 70,266,761
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga

Performance

YTD
-60.37%
-60.37%
1 Month
-26.38%
-26.38%
3 Month
-48.81%
-48.81%
6 Month
-60.25%
-60.25%
1 Year
-56.93%
-56.93%

More News

Read More
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
Via Investor's Business Daily
Expert Ratings For Beam Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Via Investor's Business Daily
Pfizer Continues Its Covid Makeover: What's Next For This Hot Stock?
Via Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Via Investor's Business Daily
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
Via Benzinga
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
Via Investor's Business Daily
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
Via InvestorPlace
Got $1,000? Check Out These 3 Top Biotech Stocks
Via The Motley Fool
Being First Is Not Enough For Crispr Therapeutics
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Via Benzinga
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
Via Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
Via The Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
Via Benzinga
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Via Benzinga
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
Via The Motley Fool
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Via Benzinga
Beam Therapeutics Stock Flashes Renewed Technical Strength
Via Investor's Business Daily
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Via Benzinga
Exposures COVID-19
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.